Previous 10 | Next 10 |
home / stock / bpmuf / bpmuf news
Clinical portfolio substantially strengthened through business development in 2023; two phase 3 studies expected to start in 2024 Cresemba in-market sales of USD 445 million, increased 22% year-on-year, in 12-month period ending September 2023; 6-months market exclusivity extension grante...
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today...
Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. ...
Allschwil, Switzerland, November 20, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the...
2023-11-13 08:19:26 ET Swiss biotech Basilea Pharmaceutica (OTC:BPMUF) and Pfizer (NYSE:PFE) subsidiary Amplyx Pharmaceuticals have inked a deal worth $37 million, granting Basilea rights to Fosmanogepix, a Phase 3 ready broad-spectrum antifungal. The agreement, announced on Monday,...
2023-11-13 07:30:51 ET More on Basilea Pharmaceutica AG Basilea Pharmaceutica AG (BPMUF) Q2 2023 Earnings Call Transcript Historical earnings data for Basilea Pharmaceutica AG Financial information for Basilea Pharmaceutica AG For further details see: Pfi...
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 13, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today...
Exclusive license to evaluate tonabacase in preclinical studies Exclusive option to license tonabacase at pre-agreed terms Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 31, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commer...
New compound added to Basilea’s clinical pipeline; upon successful completion of preclinical profiling, start of phase 2 study planned for H1 2025 Upfront payments of USD 2 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 19, 2023...
Eight presentations on antibiotic ceftobiprole providing further evidence for its activity against methicillin-resistant Staphylococcus aureus (MRSA) and other clinically relevant pathogens Allschwil, Switzerland, October 17, 2023 Basilea Pharmaceutica Ltd, Allschw...
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its anti...
Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combati...
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today th...